An optional 1-year extension aims at assessing: (1) Sustainability of above mentioned parameters over a second year of HCL use in the group who started HCL early after diagnosis, (2) Efficacy on glucose control according to the above mentioned parameters when HCL is initiated early after diagnosis vs. after 1 year in the control group of the randomized phase. conditions: Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized control study in parallel groups, followed by a non randomized extension primaryPurpose: TREATMENT masking: NONE count: 112 type: ESTIMATED name: OmniPod 5 name: Dexcom G6 name: PAID questionnaires measure: Glycated hemoglobin (HbA1c) level measure: Percent of time spent in the 70-180 mg/dl glucose range measure: Percent of time spent in the 70-140 mg/dl glucose range measure: Mean glucose level measure: Percent of time spent with glucose level below 70 mg/dl measure: Percent of time spent with glucose level below 54 mg/dl measure: Percent of time spent with glucose level above 180 mg/dl measure: Percent of time spent with glucose level above 250 mg/dl measure: Coefficient of glucose variability measure: Score of PAID questionnaire for parents measure: Score of PAID questionnaire for children measure: Stimulated plasma C-peptide level 10-min after 1mg IV glucagon measure: Number of needed interventions by the parents/guardians or care providers measure: Change of HbA1c level between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of percent of time spent in the 70-180 mg/dl glucose range between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of percent of time spent in the 70-140 mg/dl glucose range between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of mean glucose level between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of percent of time spent with glucose level below 70 mg/dl between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of percent of time spent with glucose level below 54 mg/dl between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of percent of time spent with glucose level above 180 mg/dl between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of percent of time spent with glucose level above 250 mg/dl between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of coefficient of glucose variability between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of score of PAID questionnaire for parents between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of score of PAID questionnaire for children between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of stimulated plasma C-peptide level 10-min after 1mg IV glucagon between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Change of number of needed interventions by the parents/guardians or care providers between 1st and 2nd year of use in the group who started HCL early after diagnosis measure: Difference in the HbA1c level between the 2 initially randomized groups at the end of the extension period measure: Difference in the percent of time spent in the 70-180 mg/dl glucose range between the 2 initially randomized groups at the end of the extension period measure: Difference in the percent of time spent in the 70-140 mg/dl glucose range between the 2 initially randomized groups at the end of the extension period measure: Difference in the mean glucose level between the 2 initially randomized groups at the end of the extension period measure: Difference in the percent of time spent with glucose level below 70 mg/dl between the 2 initially randomized groups at the end of the extension period measure: Difference in the percent of time spent with glucose level below 54 mg/dl between the 2 initially randomized groups at the end of the extension period measure: Difference in the percent of time spent with glucose level above 180 mg/dl between the 2 initially randomized groups at the end of the extension period measure: Difference in the percent of time spent with glucose level above 250 mg/dl between the 2 initially randomized groups at the end of the extension period measure: Difference in the coefficient of glucose variability between the 2 initially randomized groups at the end of the extension period measure: Difference in the score of PAID questionnaire for parents between the 2 initially randomized groups at the end of the extension period measure: Difference in the score of PAID questionnaire for children between the 2 initially randomized groups at the end of the extension period measure: Difference in the stimulated plasma C-peptide level 10-min after 1mg IV glucagon between the 2 initially randomized groups at the end of the extension period measure: Difference in the number of needed interventions by the parents/guardians or care providers between the 2 initially randomized groups at the end of the extension period measure: Incidence of treatment-emergent SUSARs, SAEs, ARs and AEs measure: Relatedness of treatment-emergent SUSARs, SAEs, ARs and AEs measure: Severity of treatment-emergent SUSARs, SAEs, ARs and AEs sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: University Hospital, Angers city: Angers country: France name: Régis Coutant, MD role: CONTACT phone: 02 41 35 56 55 phoneExt: +33 email: recoutant@chu-angers.fr lat: 47.46667 lon: -0.55 facility: University Hospital, Montpellier city: Montpellier country: France name: Eric Renard, MD role: CONTACT phone: 04 67 33 83 82 phoneExt: +33 email: e-renard@chu-montpellier.fr lat: 43.61092 lon: 3.87723 facility: Robert Debré Hospital, AP-HP city: Paris country: France name: Elise Bismuth Reisman, MD role: CONTACT phone: 01 40 03 20 67 phoneExt: +33 email: elise.bismuth@aphp.fr lat: 48.85341 lon: 2.3488 facility: University Hospital, Tours city: Tours country: France name: Yannis Chartier, MD role: CONTACT phone: 06 85 67 93 35 phoneExt: +33 email: Y.CHARTIER@chu-tours.fr lat: 47.38333 lon: 0.68333 hasResults: False